Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
Journal
Hepatology International
Journal Volume
10
Journal Issue
2
Pages
258-266
Date Issued
2016
Author(s)
Yang S.-S.
Abstract
The treatment of chronic hepatitis C is revolutionizing rapidly. The aim of this study is to review the efficacy and safety of daclatasvir (DCV)-containing all-oral regimens in clinical studies for chronic hepatitis C treatment. Using PubMed and search terms of ‘DCV,’ ‘hepatitis C virus (HCV) treatment,’ and ‘HCV NS5A inhibitors,’ literature on the clinical development of DCV, as well as abstracts presented at the April 2015 annual meeting of the European Association for the Study of the Liver (EASL) and November 2014 annual meeting of the American Association for the Study of Liver Diseases were reviewed. The final search was undertaken on 14 July 2015. With its potent antiviral activity to all HCV genotypes (GT) demonstrated in preclinical, phases 1–3 studies, DCV has been acting as a very competent team player in clinical trials of all-oral regimens. It is generally safe and well tolerated with a low genetic barrier to resistance and low potential for drug–drug interaction. Administered with a non-structural protein 3 (NS3) protease inhibitor (asunaprevir, ASV) with or without a non-nucleoside NS5B polymerase inhibitor (beclabuvir, BCV), or a nucleotide NS5B polymerase inhibitor (sofosbuvir, SOF), DCV is able to achieve greater than a 90-% HCV eradication rate in both treatment-na?ve and treatment-experienced patients with GT 1. A triple combination regimen with DCV/ASV/BCV results in 100?% sustained virologic response (SVR) rates in HCV GT 4 treatment-na?ve subjects. DCV/SOF combination also had demonstrated up to 90-% SVR rates in GT 3-infected non-cirrhotic patients. The efficacy and safety of DCV-containing all-oral regimens highlight a new era of interferon-free therapy for chronic hepatitis C. ? 2015, Asian Pacific Association for the Study of the Liver.
Subjects
Daclatasvir; Genotype; Hepatitis C virus; Interferon; NS5A inhibitor
SDGs
Other Subjects
asunaprevir; beclabuvir; boceprevir; daclatasvir; nonstructural protein 3; nonstructural protein 5A inhibitor; sofosbuvir; 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide; antivirus agent; asunaprevir; benzazepine derivative; BMS-790052; imidazole derivative; indole derivative; isoquinoline derivative; sofosbuvir; sulfonamide; antiviral activity; diarrhea; disease eradication; drug efficacy; drug mechanism; drug metabolism; drug safety; drug structure; drug tolerability; EC50; fatigue; genotype; headache; hepatitis C; Hepatitis C virus; human; nausea; phase 1 clinical trial; phase 2 clinical trial; phase 3 clinical trial; priority journal; Review; treatment response; virus load; virus replication; clinical trial (topic); combination drug therapy; drug interaction; Hepacivirus; Hepatitis C, Chronic; isolation and purification; oral drug administration; treatment outcome; Administration, Oral; Antiviral Agents; Benzazepines; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Sofosbuvir; Sulfonamides; Treatment Outcome
Publisher
Springer India
Type
review